#ECFS2018 – Kalydeco’s Benefits Include Lower Risk of Death and Pulmonary Flares, Real-world Data Shows Jun 08, 2018 10:00 am | Patricia Inacio, PhD

Real-world results from the largest analyses of Vertex Pharmaceutical’s cystic fibrosis’ treatment Kalydeco (ivacaftor) done in CF patients to date confirm the therapy’s ability to significantly lower the risks of mortality, transplants, hospitalization, and pulmonary exacerbations compared to untreated patients. These results were presented today at the 41st European Cystic Fibrosis Society (ECFS) Conference, taking place through June 9 […] The post #ECFS2018 – Kalydeco’s Benefits Include Lower Risk of Death and Pulmonary Flares, Real-world Data Shows appeared first on Cystic Fibrosis News Today.

Read More

#ECFS2018 – Kalydeco’s Benefits Include Lower Risk of Death and Pulmonary Flares, Real-world Data Shows

JUNE 8, 2018

BY PATRICIA INACIO, PHD

 

IN CYSTIC FIBROSIS, NEWS.